Venture Life Group (LON:VLG) Hits New 1-Year High - Time to Buy?

Key Points

• Venture Life Group plc reached a new 52-week high of GBX 63 ($0.83) during trading, with the last trade at GBX 61.25 ($0.81) on a volume of 739,734 shares.
• The company reported quarterly earnings of GBX 3.96 ($0.05) EPS and maintains a debt-to-equity ratio of 28.45 with a market cap of £78.05 million.
• Insider Jerry Randall purchased 50,000 shares at an average price of GBX 59 ($0.78), indicating confidence in the stock, which has 10.41% insider ownership.

Venture Life Group plc (LON:VLG - Get Free Report) hit a new 52-week high during trading on Friday . The stock traded as high as GBX 63 ($0.83) and last traded at GBX 61.25 ($0.81), with a volume of 739734 shares traded. The stock had previously closed at GBX 60 ($0.79).

Venture Life Group Stock Up 2.1%

The company has a debt-to-equity ratio of 28.45, a current ratio of 2.22 and a quick ratio of 1.48. The company has a market cap of £78.05 million, a PE ratio of 103.94, a price-to-earnings-growth ratio of 5.67 and a beta of 0.30. The company has a fifty day moving average price of GBX 54.47 and a 200 day moving average price of GBX 45.24.

Venture Life Group (LON:VLG - Get Free Report) last issued its quarterly earnings data on Monday, June 30th. The company reported GBX 3.96 ($0.05) EPS for the quarter. Venture Life Group had a return on equity of 0.99% and a net margin of 1.44%. As a group, analysts anticipate that Venture Life Group plc will post 6.1391542 EPS for the current year.

Insider Transactions at Venture Life Group

In other news, insider Jerry Randall bought 50,000 shares of the business's stock in a transaction on Wednesday, July 2nd. The stock was acquired at an average price of GBX 59 ($0.78) per share, with a total value of £29,500 ($38,969.62). 10.41% of the stock is currently owned by corporate insiders.

Venture Life Group Company Profile

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.